NKY(SZ:300109) Shang Hai Zheng Quan Bao·2025-04-18 22:20Core Viewpoint - The company has reported its annual financial results, highlighting its main business areas in fine chemicals and precision medicine, along with a proposed cash dividend distribution to shareholders [1][25]. Company Overview - The company specializes in fine chemicals and precision medicine, being the first in China to focus on the production, research, and sales of PVP series products and PVME/MA series products [5][25]. - The main products include PVP, which is widely used in pharmaceuticals, food processing, cosmetics, new energy, environmental water treatment, and other industrial fields [6][20]. Financial Highlights - The company has proposed a cash dividend of 2.5 yuan per 10 shares (including tax) based on a total of 484,700,005 shares, with no stock bonus [4][31]. - The company has undergone a change in its auditing firm to Zhongqin Wanxin Certified Public Accountants [3]. Business Applications - PVP products are utilized in various sectors: - Pharmaceuticals: Used as binders, stabilizers, and release agents in drug formulations [6][7]. - Food Processing: Acts as a clarifying agent and stabilizer [8][9]. - Cosmetics: Functions as a thickening agent and moisture-retaining agent [10][11]. - New Energy: Serves as a dispersant in lithium batteries and enhances photovoltaic cell efficiency [12][13]. - Environmental Treatment: Used in membrane materials and as inhibitors in gas transportation [14][15]. - Other Industries: Improves the performance of coatings, inks, textiles, and paper [16][18][19]. Strategic Developments - The company has approved investments in two entities, increasing its stake in Huadao Biological and Zhongqi Huiyun Technology [29]. - The company is focusing on expanding its precision medicine services, leveraging its technology in equipment, reagents, and medical services [24].